title: Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.
abstract: BACKGROUND
  The epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase (TK) receptor that mediates proliferation and survival signaling, is expressed in a wide variety of normal and neoplastic tissues. EGFR inhibitors have produced objective responses in patients with non-small-cell lung carcinomas harboring activating EGFR TK domain somatic mutations.
  
  
  OBJECTIVE
  Because the EGFR pathway has been reported to be important for the pathophysiology of thyroid carcinoma, we investigated the expression and mutational status of EGFR in 14 thyroid carcinoma cell lines as well as its functional role by evaluating their in vitro sensitivity to AEE788, a new dual-family EGFR/ErbB2 and vascular endothelial growth factor receptor TK inhibitor. We also evaluated the mutational status, mRNA and protein expression, as well as phosphorylation status of EGFR in a panel of thyroid carcinoma specimens.
  
  
  RESULTS
  EGFR expression and phosphorylation in the thyroid carcinoma cell lines and tissue specimens were present but not stronger than in noncancerous thyroid tissue. EGFR TK domain mutations were detected in two of 62 histological specimens (3.2%) but not in cell lines. All thyroid carcinoma cell lines were significantly less sensitive (IC(50) at least 25-fold higher) in vitro to AEE788 than a primary culture of EGFR-mutant lung carcinoma cells.
  
  
  CONCLUSIONS
  Thyroid carcinoma cells overall are poorly responsive to clinically relevant concentrations of AEE788 in vitro. The presence of EGFR-activating TK domain mutations may identify a small minority of thyroid cancer patients that may benefit from EGFR inhibitors, but additional preclinical evidence of efficacy is needed.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Mayer Building, Room M555, 44 Binney Street, Boston, Massachusetts 02115, USA. Constantine_Mitsiades@dfci.harvard.edu
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Mitsiades
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Kotoula
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Poulaki
authors.forename: Elias
authors.initials: E
authors.lastname: Sozopoulos
authors.forename: Joseph
authors.initials: J
authors.lastname: Negri
authors.forename: Elpida
authors.initials: E
authors.lastname: Charalambous
authors.forename: Galinos
authors.initials: G
authors.lastname: Fanourakis
authors.forename: Gerassimos
authors.initials: G
authors.lastname: Voutsinas
authors.forename: Sophia
authors.initials: S
authors.lastname: Tseleni-Balafouta
authors.forename: Nicholas
authors.initials: N
authors.lastname: Mitsiades
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016328:NF-kappa B / Q000378:metabolism; D051058:Oncogene Protein v-akt / Q000378:metabolism; D010766:Phosphorylation; D017434:Protein Structure, Tertiary; D011687:Purines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D016328:NF-kappa B; D011687:Purines; D012333:RNA, Messenger; D066246:ErbB Receptors; D051058:Oncogene Protein v-akt; C489254:AEE 788